University of Texas/Texas AM Investment Management Co (UTIMCO) Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$825K |
| 2 |
Stryker
SYK
|
+$701K |
| 3 |
APEN
Apollo Endosurgery, Inc.
APEN
|
+$523K |
| 4 |
XYZ
Block Inc
XYZ
|
+$38.3K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$52.7M |
| 2 |
Spyre Therapeutics
SYRE
|
+$327K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 52.51% |
| 2 | Healthcare | 31.56% |
| 3 | Technology | 15.91% |
| 4 | Utilities | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vanguard Total World Stock ETF
VT
$81.7B
| $13.6M | 52.51% |
181,558
| – | – |
|
2
Texas Instruments
TXN
$254B
| $4.06M | 15.71% |
32,000
| – | – |
|
|
SOLY
3
DELISTED
Soliton, Inc.
SOLY
| $3.31M | 12.79% |
425,000
| – | – |
|
|
4
Spyre Therapeutics
SYRE
$7.56B
| $2.59M | 10% |
11,187
-1,719
| -13% | -$327K |
|
|
5
Amgen
AMGN
$224B
| $853K | 3.3% |
+3,615
| New | +$825K |
|
|
6
Stryker
SYK
$104B
| $685K | 2.65% |
+3,800
| New | +$701K |
|
|
APEN
7
DELISTED
Apollo Endosurgery, Inc.
APEN
| $456K | 1.76% |
279,037
+263,436
| +1,689% | +$523K |
|
|
PLXP
8
DELISTED
PLx Pharma Inc. Common Stock
PLXP
| $203K | 0.78% |
62,673
| – | – |
|
9
Lexicon Pharmaceuticals
LXRX
$796M
| $71K | 0.27% |
35,714
| – | – |
|
|
XYZ
10
Block Inc
XYZ
$45.9B
| $52K | 0.2% |
+500
| New | +$38.3K |
|
11
Portland General Electric
POR
$5.51B
| $5K | 0.02% |
118
| – | – |
|
|
12
State Street SPDR S&P 500 ETF Trust
SPY
$796B
| – | – |
-204,446
| Closed | -$52.7M |
|
Similar funds
University of Texas/Texas AM Investment Management Co (UTIMCO)'s Q2 2020 Portfolio in Review
As of Q2 2020, University of Texas/Texas AM Investment Management Co (UTIMCO) held 12 positions worth $25.9M, down 64% from $72.5M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
University of Texas/Texas AM Investment Management Co (UTIMCO) withdrew a net $50.9M in Q2 2020, closing 1 position and reducing 1 holding. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $52.7M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 53% of assets, down from 88% a quarter earlier, followed by Healthcare and Technology.
Against the trend, University of Texas/Texas AM Investment Management Co (UTIMCO) opened a new position in Amgen worth $853K.
- University of Texas/Texas AM Investment Management Co (UTIMCO)'s largest Q2 2020 buy was Amgen: 3,615 shares worth $853K.
- University of Texas/Texas AM Investment Management Co (UTIMCO) added most to Apollo Endosurgery, Inc. in Q2 2020, an estimated $523K increase.
- University of Texas/Texas AM Investment Management Co (UTIMCO)'s biggest Q2 2020 reduction was Spyre Therapeutics, cutting an estimated $327K.
- University of Texas/Texas AM Investment Management Co (UTIMCO) fully exited State Street SPDR S&P 500 ETF Trust in Q2 2020, selling an estimated $52.7M.
- University of Texas/Texas AM Investment Management Co (UTIMCO)'s ten largest holdings make up 100% of its $25.9M portfolio in Q2 2020.
- University of Texas/Texas AM Investment Management Co (UTIMCO) opened 3 new positions and closed 1 in Q2 2020.
- University of Texas/Texas AM Investment Management Co (UTIMCO)'s portfolio value fell 64% quarter-over-quarter to $25.9M.
Based on University of Texas/Texas AM Investment Management Co (UTIMCO)'s 13F filing for Q2 2020, filed 4 Aug 2020.